Vaccinex Inc. (NASDAQ: VCNX)
$6.29
-0.2850 ( -4.33% ) 13.8K
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Market Data
Open
$6.29
Previous close
$6.58
Volume
13.8K
Market cap
$9.90M
Day range
$6.14 - $6.86
52 week range
$4.43 - $68.46
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Apr 01, 2024 |
8-k | 8K-related | 21 | Apr 01, 2024 |
4 | Insider transactions | 1 | Apr 01, 2024 |
8-k | 8K-related | 15 | Mar 28, 2024 |
8-k | 8K-related | 13 | Mar 27, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
4 | Insider transactions | 1 | Mar 22, 2024 |
3 | Insider transactions | 2 | Mar 14, 2024 |